Pfizer announces €1.2 billion investment and hundreds of jobs at Grange Castle site
Thursday, 1st December 2022 – Pfizer Inc. today announced its intent to invest more than €1.2 billion capital investment in its Grange Castle, Dublin manufacturing site. The investment, which is Pfizer’s biggest expansion investment to date in Ireland, will see a new facility built on the site premises and will double the capacity for biological drug substance manufacturing at the facility. It is anticipated that there will be a further 400-500 roles added, bringing the total number of Pfizer employees in Ireland to approximately 5,500.
The investment and the roles being created will significantly expand manufacturing and laboratory capacity and add new technologies to help ensure Pfizer is ready to support the next wave of medical innovations. The project is currently in preliminary design phase with construction expected to commence onsite in 2024 and the new facility due for completion in 2027. The investment will ensure that Pfizer has capacity for licensed and pipeline products in oncology, rare disease, inflammation & immunology and internal medicines.
This announcement follows a €40 million investment in the site last year when the Grange Castle facility was brought onto the Global Pfizer COVID-19 manufacturing network. Grange Castle as well as Pfizer’s other manufacturing sites in Newbridge, Co. Kildare and Ringaskiddy, Co. Cork manufacture medicines and vaccines in the areas of arthritis, inflammation, cancer, anti-infectives, haemophilia, pain and stroke.
An Taoiseach Micheál Martin commented: “This is a really significant investment and jobs announcement by Pfizer – its biggest ever expansion in Ireland – and a considerable vote of confidence in the talent of our workforce, and our economy. Pfizer has played an instrumental role during the pandemic. It is pleasing to see just how much scientific progress has been made over the last number of years, and I have no doubt that Ireland will continue to be at the forefront of scientific innovation. I wish all the team at Pfizer here in Ireland continued success as they work towards improving the lives of patients in Ireland and beyond.”
Mike McDermott, Chief Global Supply Officer, Executive Vice President, Pfizer said: “We are very pleased about today’s announcement, as it significantly strengthens our operations in Ireland, where we have three high-performing and strategic manufacturing sites. Grange Castle has played a critical role in our global COVID-19 vaccine network, and this investment for non-COVID licensed and pipeline products, will help to further expand the site’s broad and robust capabilities. As this investment demonstrates, we continue to invest in our global manufacturing infrastructure to strive to bring much-needed medicines and vaccines to patients, around the world, and to deliver the next scientific breakthroughs.”
Details of all current roles are available on careers.pfizer.com.
Natalie Tennyson / Karen O’Keeffe, Pfizer Corporate Affairs
E: [email protected] / [email protected]
T: 083 1271277 / 086 8574291
About Pfizer in Ireland:
Pfizer is one of Ireland's largest pharmaceutical sector investors and employers. One of the first pharmaceutical companies to locate in Ireland (1969), Pfizer has 5,000 colleagues across 5 locations based in Cork, Dublin, and Kildare. Total capital investment by the company in Ireland exceeds $9 billion. Pfizer's business interests in Ireland are diverse and include manufacturing, shared (financial) services, scientific research and development (R&D) and commercial operations. Part of Pfizer's Worldwide Research & Development (WR&D) is based in Ireland - the Global Biotherapeutics Technology group at Grange Castle was established in 2006 and is part of a world-leading protein drug discovery unit within Pfizer WR&D.
The information contained in this release is as of December 1, 2022. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.
This release contains forward-looking information about Pfizer’s Grange Castle, Dublin, manufacturing site, including an investment in the Grange Castle, Dublin manufacturing site, and Pfizer’s efforts to expand manufacturing and laboratory capacity and add new technologies, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development; risks related to the ability to realize the anticipated benefits of the investment and the manufacturing site; risks related to Pfizer’s business and prospects, adverse developments in Pfizer’s markets, or adverse developments in the U.S. or global capital markets, credit markets, regulatory environment or economies generally; the impact of COVID-19 on our business, operations and financial results; and competitive developments.
A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.
Published: 1st December 2022.